SUMMARY
INTRODUCTION
Dynorphins are endogenous opioid peptides encoded by a common proenkaphalin-B gene (hereafter referred to as preprodynorphin, PDYN) (Civelli et al., 1985) that is widely expressed in the central and peripheral nervous systems of vertebrates (Cone et al., 1982; Goldsmith et al., 1992; Dores et al., 2004; Shirayama et al., 2004; Alrubaian et al., 2006) . As for various peptide hormones, dynorphins are synthesized as large, biologically inert precursor proteins that undergo post-translational modifications to produce biologically active molecules. In mammals, these active products include bigdynorphin, dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) , dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) , dynorphin B , dynorphin B (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) and -neo-endorphin (Schwarzer, 2009) . Cloning and sequence analysis of the preprodynorphin cDNA revealed that it is a highly conserved gene, although some discrepancies have been described in lower ectotherms. In fish and amphibians, the gene encoding PDYN contains an additional opioid sequence for leucine-enkephalin or isoleucine-enkephalin (Dores et al., 2004; Alrubaian et al., 2006) and for methionine-enkephalin (Danielson et al., 2002) , respectively. Although the gene encoding PDYN has not been cloned to date in reptiles, different dynorphins such as -neo-endorphin, dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) and dynorphin B (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) in the lizard Anolis carolinensis and -neo-endorphin and dynorphin B (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) in turtle and alligator have been demonstrated by Goldsmith and colleagues (Goldsmith et al., 1992) using an heterologous radioimmunoassay. Owing to its higher potency (James et al., 1984) and conserved nature, dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) [dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) ] was used here to examine its immunomodulatory role in the wall lizard H. flaviviridis.
In addition to an analgesic effect (Knoll and Carlezon, 2010) , a role for dynorphins in the regulation of immune responses has emerged in recent years (Casellas et al., 1991; Ichinose et al., 1995; Singh and Rai, 2010) . Furthermore, functional -, -and -opioid receptors belonging to the G-protein-coupled receptor (GPCR) superfamily (Law et al., 2000) have been demonstrated to be expressed by immune cells (Martin-Kleiner and Gabrilovac, 1997) . Interestingly, the same intracellular signaling cascade for different opioid receptors (Lawrence and Bidlack, 1993; Sharp et al., 1996; Wang et al., 2003) and multiple downstream signaling mechanisms for the same opioid receptor (Bohn et al., 2000; Kam et al., 2004) have been reported, depending on which mammalian cell lines were studied. With regard to ectotherms, currently there is only one report exploring the intracellular signaling cascade for -endorphin action on immune cells (Kumar et al., 2011) . In the present in vitro study, we aimed to understand the mechanism of action of receptor-coupled downstream signaling for dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) in lizard splenic phagocytes.
The adaptive immune system in ectotherms, unlike that of endothermic vertebrates, is poorly developed (Flajnik, 1996) . Therefore, innate immunity, the first line of host defense plays a crucial role in protecting ectothermic vertebrates from microbial infections. Phagocytes are an important constituent of the innate immune system. These cells possess a remarkable property to phagocytose and kill microbes. Furthermore, the phagocytic process initiates an array of events, including antigen presentation and secretion of various cytokines, which, in turn, activate the adaptive immune system. Thus, phagocytosis can be considered as a central phenomenon for the activation of the immune system during pathogenic attack. Bearing this in mind, the phagocytic activity of splenic phagocytes was selected as the parameter of study in the present investigation.
MATERIALS AND METHODS Animals
Specimens of the Indian wall lizard, Hemidactylus flaviviridis Rüppell 1835, possessing a body mass of 8-10g (adults) were procured from suburbs of Delhi, India (28°12Ј to 28°53ЈN, 76°50Ј to 77°23ЈE). They were maintained in wooden cages fitted with mesh wire from the top, sides and front for proper air circulation and light. Lizards were acclimated to the laboratory conditions (12h:12h light:dark photoperiod, lights on at 07:00h and room temperature) for one week before experiments. Animals were provided with live house flies as food, and water ad libitum. Only female lizards were used in the present in vitro study, as they show better immune responses than males (Mondal and Rai, 1999) . The Institutional Animal Ethics Committee guidelines of the University of Delhi were followed with regard to the maintenance and killing of wall lizards. In order to minimize the effects related to diurnal variation with respect to the expression of opioid receptors, and their affinity to ligand or antagonists, lizards were vivisected between 10:00 and 11:00h for all experiments.
Reagents and culture medium
All regular-use chemicals were of molecular biology grade. 
Preparation of lizard splenic phagocyte monolayer
The wall lizards were vivisected by cervical dislocation, their spleens were dissected out, pooled in chilled phosphate-buffered saline (PBS, pH7.2) and passed through nylon mesh (pore size 90m) in icecold complete culture medium to prepare the single-cell suspension. The total cell number was adjusted to 10 6 cellsml -1 . For the preparation of the phagocyte monolayer, 200l of splenocyte suspension was flooded on each pre-washed slide. Following incubation for 90min, the non-adhered cells were washed off with PBS. The viability of the adhered cell population was >98% as assessed by a Trypan Blue exclusion test. All the incubations were performed at 25°C in a humidified chamber or incubator maintained with 5% CO 2 .
Preparation of yeast cell suspension
Yeast (Saccharomyces cerevisiae) cell suspension was prepared by warming commercially available baker's yeast (1.5mgml -1 PBS) at 80°C for 20min. The heat-killed yeast cell suspension was washed and resuspended in the complete culture medium.
Phagocytic assay
For the phagocytic assay, 400l heat-killed yeast cell suspension was flooded on a phagocyte monolayer of each slide. After incubation for 90min, non-phagocytosed yeast cells were washed off with PBS. Thereafter, the phagocyte monolayer was fixed in methanol, stained with Giemsa and mounted in DPX. Cells were observed under the microscope (Nikon E400, Japan) at a magnification of ϫ400. Phagocytes engulfing one or more than one yeast cell were considered as 'positive phagocytes'. These cells possess the extending pseudopodia forming the phagocytic cup(s) to phagocytose the yeast cells (Fig.1 ). Phagocytes that were not phagocytosing the yeast cell(s) were regarded as 'negative phagocytes'. Without any predetermined sequence or scheme, ~200
S. Kumar and U. Rai phagocytes were counted per slide. The experimenter was blind to the technical details of the slides. The percentage phagocytosis and phagocytic index were calculated using established formulae (Campbell et al., 2003) : (1) percentage phagocytosis equals the number of positive phagocytes per 100 phagocytes counted; and (2) the phagocytic index is the average number of yeast cells engulfed by each positive phagocyte multiplied by the percentage phagocytosis.
In vitro experiments
Effect of dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) Splenic phagocytes were treated with varying concentrations of dyn A ( ) for 30min. Cells were washed with PBS and processed for the phagocytic assay. A phagocyte monolayer incubated in medium alone for the same duration was considered to function as a control. The concentration range of dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) used in the present in vitro study was determined after reviewing the literature (Casellas et al., 1991; Szabo et al., 1993) , whereas the optimum time required for incubation of phagocytes with dyn A (1-17) was determined based on pilot experiments.
Effect of the non-selective opioid receptor antagonist
In order to explore the involvement of opioid and non-opioid receptors in mediating the effect of dyn A (1-17) on phagocytosis, the non-selective opioid receptor antagonist naltrexone was used along with the most effective concentration of dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Splenic phagocytes were incubated with 10 -8 moll -1 naltrexone and 10 -9 moll -1 dyn A (1-17) , simultaneously, for 30min. In order to compare the results between different treatment groups, phagocytes were incubated in medium, naltrexone or dyn A (1-17) alone for 30min as controls. After incubation, cells were washed and processed for the phagocytic assay.
Effect of selective opioid receptor antagonists
Splenic phagocytes were incubated with a 10 -8 moll -1 concentration of selective -, -or -opioid receptor blocker (CTAP, NTI or NorBNI, respectively) and 10 -9 moll -1 dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , simultaneously, for 30min. For controls, phagocytes were incubated in medium, dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) or -, -or -opioid receptor blocker alone for 30min. Thereafter, phagocytes were washed and processed for the phagocytic assay. moll -1 dyn A (1-17) for 30min. The cells were washed, lysed with 0.1moll -1 HCl and centrifuged at 600g for 10min at room temperature. The cAMP in the supernatant was estimated using a commercially available enzyme immunoassay cAMP kit.
MTT assay
The method of Mosmann (Mosmann, 1983) for MTT assay was followed to verify the viability of splenic phagocytes after treatment with dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . In brief, a 100l splenocyte suspension was added to a 96-well tissue-culture plate for the preparation of a phagocyte monolayer. The non-adhered cells were washed off with PBS. Adhered phagocytes were incubated with medium alone (control) and different concentrations of dyn A (1-17) for 30min. Afterwards, splenic phagocytes were washed and incubated in 100l of medium containing 0.5mgml -1 MTT for 2h. Next, the cells were washed with PBS and permeabilized by adding 20l of 0.1% Triton X-100. The reduced product formazan was solubilized in 150l of DMSO. Following incubation for 15min at room temperature, absorbance was measured at 570nm using an ELISA plate reader (MS 5608A, ECIL, New Delhi, India).
The MTT assay is based on the ability of the mitochondrial enzyme succinate dehydrogenase in live cells to reduce MTT into a membraneimpermeable and insoluble purple crystal called formazan. The number of live cells is directly related to the amount of formazan produced.
Statistical analysis
Each treatment was performed in triplicate. All the experiments were repeated three times. The data of three independent experiments were pooled, analysed by one-way analysis of variance (ANOVA) followed by a Newman-Keuls multiple range test, and represented as means ± s.e.m. A Student's t-test was used to compare the means of two groups in the case of cAMP estimation.
RESULTS

Effect of dyn A (1-17)
Dyn A (1-17) in a concentration-dependent manner inhibited the percentage phagocytosis and phagocytic index (ANOVA, P<0.001; Fig.2 ). In comparison with a control, a marked (P<0.05) decrease in phagocytic activity was observed at a 10 
moll
-1 dyn A (1-17) , not significant]. Furthermore, a MTT assay indicated that dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) itself, in the range of the concentrations used, does not influence the cell viability (data not shown).
Effect of non-selective opioid receptor blocker
The non-selective opioid receptor antagonist naltrexone alone did not affect the phagocytic activity of splenic phagocytes (control vs naltrexone 10 moll -1 H-89, P<0.05; Fig.5 ]. Dyn A (1-17) -induced inhibition of phagocytosis was completely abolished at higher concentrations of SQ22536 or H-89 (Fig.5) 
Intracellular cAMP
In comparison with a control, a marked (P<0.01) increase in intracellular cAMP content was recorded in splenic phagocytes incubated with dyn A (1-17) for 30min (Fig.6 ).
DISCUSSION
Our in vitro study, for the first time in reptiles, has demonstrated the role of dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) and its downstream signaling cascade in the S. Kumar and U. Rai regulation of an innate immune function -phagocytosis. In the wall lizard H. flaviviridis, dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) by acting through the -opioid receptor inhibited the phagocytosis of yeast cells by splenic phagocytes. This is in contrast to data reported in fish (Singh and Rai, 2010) and mammals (Ichinose et al., 1995), wherein, dyn A (1-17) stimulated the phagocytosis of yeast cells by fish splenic phagocytes (Singh and Rai, 2010) and latex particles by murine peritoneal macrophages (Ichinose et al., 1995) . With respect to receptormediated action, dyn A (1-17) stimulated the phagocytosis through a -opioid receptor in fish only. Interestingly, in mammals, the stimulatory effect of dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) was mediated through a non-opioid receptor as the non-selective opioid receptor blocker naltrexone failed to block the effect of dyn A (1-17) on phagocytosis (Ichinose et al., 1995) . Nevertheless, a specific opioid-receptor-mediated inhibitory effect of dynorphin(s) and its receptor agonist on phagocytosis has been reported in mammals. Dyn A (1-13) and a -opioid receptor agonist were shown to inhibit the phagocytosis of sheep erythrocytes (Casellas et al., 1991) and Candida albicans (Szabo et al., 1993) by murine peritoneal macrophages. In both the cases, the effect was mediated through a -opioid receptor. The reason for the diverging results pertaining to the effect of dynorphin(s) on phagocytosis might be ascribed to the involvement of different receptors (opioid or non-opioid) and also to the specificity of target cells to be phagocytosed by the immune cells. Thus, it seems that, despite the species-specific differential effect, dynorphin(s) modulate the phagocytosis largely through opioid receptors -and particularly through -opioid receptors. It is noteworthy that cDNA for opioid receptors have not been cloned to date from any reptile tissue, although they have been cloned from immune as well as non-immune cells of fish (Darlison et al., 1997; Barrallo et al., 1998; Barrallo et al., 2000; Rodriguez et al., 2000; Alvarez et al., 2006; Chadzinska et al., 2009 ) and mammals (Chuang et al., 1994; Graveriaux et al., 1995; Sedqi et al., 1995; Sedqi et al., 1996; Sharp et al., 1997; Sharp et al., 2000) . The sequence analysis of cDNA revealed that these receptors belong to the superfamily of G-protein-coupled receptors (Sharp et al., 1997; Law et al., 2000) . Generally, opioid receptors are coupled with the alpha inhibitory subunit (G i ) of the G-protein that, upon activation, downregulates the adenylate cyclase activity and, consequently, cAMP production (Lawrence and Bidlack, 1993; Sharp et al., 1996; Wang et al., 2003) . However, an accumulation of intracellular cAMP upon the activation of opioid receptors is well established in mammalian immune cells (Aymerich et al., 1998) and cell lines (Martin-Kleiner and Gabrilovac, 1997; Heagy et al., 1999) . This suggests the coupling of an opioid receptor with a stimulatory alpha subunit ( s ) of the G-protein. In our earlier in vitro study in the wall lizard, dibutyryl cAMP was shown to inhibit the percentage phagocytosis and phagocytic index at higher concentrations (Roy and Rai, 2004) . Also, an increased intracellular cAMP level in cortisoltreated (Roy and Rai, 2009 ) and melatonin-treated (Roy et al., 2008) splenic phagocytes is reported to be directly correlated with inhibition of phagocytosis in the freshwater fish Channa punctatus. In light of these studies, we speculated that dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) would have inhibited the phagocytic activity of lizard splenic phagocytes by activating the  s subunit of the G-protein coupled to -opioid receptors and, consequently, by increasing the intracellular cAMP level. This assumption was verified using the inhibitor of adenylate cyclase SQ 22536, which completely averted the inhibitory effect of dyn A (1-17) on phagocytosis. Also, an increase in the intracellular cAMP level in lizard splenic phagocytes in response to dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) reconfirmed the assumption. Furthermore, the cAMP-dependent PKA pathway was shown to be involved in mediating dyn-A (1-17) -induced inhibition of phagocytosis as the effect was fully reversed by the PKA inhibitor H-89. However, an altogether different downstream signaling cascade for dynorphins has been reported by Ichinose and colleagues (Ichinose et al., 1995) in murine peritoneal macrophages. In these cells, dynorphin stimulated the phagocytic activity by means of a non-opioid receptor-mediated calcium signaling cascade. Although further studies are required across the vertebrates to develop a deeper insight into the evolutionary aspects of the immunomodulatory role of opioids, the dynorphin effect on phagocytosis in reptiles seem to be closer to that in mammals than in fish. The present study in wall lizards reveals the involvement of the AC-cAMP-PKA pathway in transducing the inhibitory effect of dynA (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) on phagocytosis.
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